Pfizer Inc. (NYSE: PFE) and BioNTech SE’s (NASDAQ: BNTX) COVID-19 vaccine can protect against the omicron variant after two doses. This finding results from a study from Africa Health Research Institute, South Africa. The study shows that blood from people who had a previous infection and had taken two doses of the vaccine could protect people from the variant. From this, the researchers concluded that the booster could be beneficial.
The study used the blood of people who had received a booster as the booster is not available in South Africa. Despite the good news, other studies have shown negative results.
Since the omicron variant emerged, there has been concern about its severity. However, the World Health Organization (WHO) has stated that there is still no reason for a vaccine that targets it. Research done in South Africa has found that symptoms from omicron are mild. However, the virus still spreads rapidly.
The vice president of vaccines for international developed markets, Ralf Rene Reinert, has stated that Pfizer will report in 2-3 weeks if their vaccine can ward off omicron. Until then, he advises people to get a Pfizer booster.
COVID-19 cases in New Jersey Increase after Thanksgiving
The COVID-19 cases in New Jersey have gone up after the Thanksgiving holiday. The schools in the state have also reported more cases. The number is highest since the school year started.
Judy PersiChilli, the Health Commissioner of New Jersey, has asked people to wear a mask to restrict the spread of the virus. She urges people to water a mask while inside, with many people of you do not know their vaccination status. The States officials also ask people to get vaccination and boosters as the omicron and Delta variant spread within the region.
BioNTech and Pfizer trials show that a third dose of the vaccine could ward off the variant. As a result of the initial studies, South Africa has approved a third dose of the vaccine for adults.
Pfizer reaches a milestone payment after selling Cresemba
Meanwhile, Basilea Pharmaceutica (OTCMKTS: BPMUF) has announced that Pfizer, its partner, has sold its antifungal Cresemba in Israel, Russia, and Europe. The sales have led to a milestone payment of $10 million.
Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.